# Kingscrowd just rated us a 4.6/5 investment opportunity 🎉 | Sempresto

- Canonical URL: https://wefunder.com/feed/439645
- Entity ID: wefunder:feed_item:439645
- Published at: 2026-10-28 13:04:33 UTC
- Updated at: 2026-10-28 13:05:46 UTC

## Author
Elizabeth Reczek

## Subject
Sempresto

## Content
Kingscrowd, the leading independent ratings platform for online startup investing, reviews hundreds of deals a year. They just rated Sempresto 4.6 out of 5, well above the median of 3 for early stage deals. Their senior analyst, Teddy Lyons, evaluated our deal, with two sub-scores standing out:🏆Differentiation earned a perfect 5.0. Sempresto’s slim autoinjector is engineered to attach to your phone, with a companion app and 24/7 emergency telehealth. It’s backed by 15 issued patents plus 10 pending. 🥼Our team scored an outstanding 4.8. Teddy points to our depth in biotech commercialization and to Dr. Edmund Pribitkin’s clinical leadership at Jefferson Health, where our core technology was born.Teddy placed our thesis in one line: “epinephrine already works, but it cannot help if the device is somewhere else.” That is the problem Sempresto is being built to solve.Join professional and retail investors in this round: wefunder.com/sempresto With gratitude,LizElizabeth ReczekPhD Co-Founder & CEOSemprestoSempresto is an investigational product. It has not been approved by the FDA and is not available for sale.